Press Releases

Merck KGaA, Darmstadt, Germany Obtains US Antitrust Clearance for Acquisition of Sigma-Aldrich
Merck KGaA, Darmstadt, Germany Obtains US Antitrust Clearance for Acquisition of Sigma-Aldrich
Darmstadt, Germany, December 23, 2014 – Merck KGaA, Darmstadt, Germany today announced that it has obtained antitrust clearance from the United States Federal Trade Commission (FTC) for its planned acquisition of US-based life science company Sigma-Aldrich.
 
Marcus Kuhnert (CFO)
Marcus Kuhnert Member of the Executive Board - Chief Financial Officer
Merck KGaA, Darmstadt,Germany, Issues Euro Hybrid Bond Amounting to € 1.5 bn
Darmstadt, Germany, December 8, 2014 – Merck KGaA, Darmstadt, Germany, today successfully issued a hybrid bond with a two-tranche structure amounting to € 1.5 bn. The issuance is part of the financing of the proposed acquisition of U.S.-based life science company Sigma-Aldrich , which was announced in September 2014.
 
Sigma - Aldrich Shareholders Approve Merger With Merck KGaA, Darmstadt, Germany
Sigma - Aldrich Shareholders Approve Merger With Merck KGaA, Darmstadt, Germany
Darmstadt, Germany, December 5, 2014 – Merck KGaA, Darmstadt, Germany, today achieved an important milestone in the process of acquiring U.S.-based life science company Sigma-Aldrich. The shareholders of Sigma-Aldrich approved the merger with Merck KGaA, Darmstadt, Germany at a special meeting held at the Sigma-Aldrich Life Science and Technology Center in St. Louis, Missouri, USA.
 
 
 
 
 
 
 
 
 
 

DISCLAIMER

Publication of Merck KGaA, Darmstadt, Germany.
In the United States and Canada the subsidiaries of Merck KGaA, Darmstadt, Germany, operate under the umbrella brand EMD.
 

CONTACTS FOR JOURNALIST INQUIRIES

Media Team
POSTAL ADDRESS 
Merck KGaA 
Frankfurter Straße 250 
64293 Darmstadt 
Germany
Tel.: +49 6151 72-5000
Fax: +49 6151 72-3138
 

FINANCIAL REPORT

2nd quarter 2014Merck Interim Report
Merck on Facebook
Merck on Twitter
 
  
Read more on M - The Explorer Magazine

Using hamster cells to fight multiple sclerosis

Michel Revel has developed the multiple sclerosis drug Rebif®. He has dedicated his entire career as a researcher to the search for MS treatments.

Read more on M - The Explorer Magazine
Read more on M - The Explorer Magazine

The car couturier shows his passion for color

The technology visionary Rainer Buchmann enhances automobiles with pearl luster effect paints containing pigments from our company.

Read more on M - The Explorer Magazine